The DOI matches its Crossref record.
Long-lasting treatment effect of rituximab in MuSK myasthenia
Abstract
OBJECTIVE: Rituximab has emerged as an efficacious option for drug-resistant myasthenia gravis (MG). However, reports published only describe the short-term follow-up of patients treated and little is known about their long-term clinical and immunologic evolution. Our objective was to report the clinical and immunologic long-term follow-up of 17 patients (6 MuSK+MG and 11 AChR+MG) and compare the response between AChR+MG and MuSK+MG patients. METHODS: Myasthenia Gravis Foundation America postintervention status and changes in treatment and antibody titers were periodically determined. Lymphocyte subpopulations, total immunoglobulin, immunoglobulin G (IgG) anti-MuSK subclasses, and anti-tetanus toxoid IgG before and after treatment were also studied. RESULTS: After a mean post-treatment period of 31 months, 10 of the AChR+MG patients improved but 6 of them needed reinfusions. In contrast, all MuSK+MG patients achieved a remission (4/6) or minimal manifestations (2/6) status and no reinfusions were needed. Consequently, in the MuSK+MG group, prednisone doses were significantly reduced and concomitant immunosuppressants could be withdrawn. Clinical improvement was associated with a significant decrease in the antibody titers only in the 6 MuSK+MG patients. At last follow-up MuSK antibodies were negative in 3 of these patients and showed a decrease of over 80% in the other 3. CONCLUSION: In view of the long-lasting benefit observed in MuSK+MG patients, we recommend to use rituximab as an early therapeutic option in this group of patients with MG if they do not respond to prednisone. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that IV rituximab improves the clinical and immunologic status of patients with MuSK+MG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Self-citationB cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Antibodies to contactin‐1 in chronic inflammatory demyelinating polyneuropathy
Querol, L., Nogales‐Gadea, G., Rojas‐Garcia, R., Martinez‐Hernandez, E., Diaz‐Manera, J., Suárez‐Calvet, X., Navas, M., Araque, J., Gallardo, E., & Illa, I. (2013) · Annals of Neurology · doi:10.1002/ana.23794 · Cited by 352
Self-citationRegulatory T cells in multiple sclerosis and myasthenia gravis
Danikowski, K. M., Jayaraman, S., & Prabhakar, B. S. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0892-8 · Cited by 323
Myasthenia gravis: an update for the clinician
Sieb, J. P. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12217 · Cited by 283
Metadata
- Authors
- Díaz-Manera, J., Martínez-Hernández, E., Querol, L., Klooster, R., Rojas-García, R., Suárez-Calvet, X., Muñoz-Blanco, J. L., Mazia, C., Straasheijm, K. R., Gallardo, E., Juárez, C., Verschuuren, J. J., & Illa, I.
- Venue
- Neurology
- Published
- 2012-01-17
- Volume
- 78
- Issue
- 3
- Pages
- 189-193
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2082722055
- Cited by
- 346
- References
- 0
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-lasting treatment effect of rituximab in MuSK myasthenia. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182407982
- The paper
- Díaz-Manera, J., Martínez-Hernández, E., Querol, L., Klooster, R., Rojas-García, R., Suárez-Calvet, X., Muñoz-Blanco, J. L., Mazia, C., Straasheijm, K. R., Gallardo, E., Juárez, C., Verschuuren, J. J., & Illa, I. (2012). Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. https://doi.org/10.1212/wnl.0b013e3182407982
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.